c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations (Q47379010)

15 January 2018

title

c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations (English)

1 reference

15 January 2018

author name string

Penelope Korkolopoulou

1

1 reference

15 January 2018

Athina Goudopoulou

2

1 reference

15 January 2018

Gerassimos Voutsinas

3

1 reference

15 January 2018

Euphemia Thomas-Tsagli

4

1 reference

15 January 2018

Panagiotis Kapralos

5

1 reference

15 January 2018

Efstratios Patsouris

6

1 reference

15 January 2018

Angelica A Saetta

7

1 reference

15 January 2018

language of work or name

English

0 references

publication date

1 June 2004

1 reference

15 January 2018

published in

Urology

1 reference

15 January 2018

volume

63

1 reference

15 January 2018

issue

6

1 reference

15 January 2018

page(s)

1198-1204

1 reference

15 January 2018

[Genetic control of programmed cell death (apoptosis). Prospects for biological tumor staging?]

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Caspases: killer proteases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Selective expression of FLIP in malignant melanocytic skin lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Transitional cell carcinoma expresses high levels of Fas ligand in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Human astrocytomas co-expressing Fas and Fas ligand also produce TGFbeta2 and Bcl-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

FAP-1: a protein tyrosine phosphatase that associates with Fas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Inhibition of death receptor signals by cellular FLIP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Death receptors: signaling and modulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Death pathway genes Fas (Apo-1/CD95) and Bik (Nbk) show no mutations in colorectal carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Lack of Fas (APO-1/CD95) gene structural alterations or transcript variant ratio changes in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

The role of c-FLIP in modulation of CD95-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Increased expression of cFLIP(L) in colonic adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Increased expression of FLIP, an inhibitor of Fas‐mediated apoptosis, in stomach cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

Factors Influencing the Survival of Patients with Transitional Cell Tumours of the Urinary Bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2004.01.007

10.1016/J.UROLOGY.2004.01.007

7 January 2021

Identifiers

DOI

1 reference

15 January 2018

PubMed ID

15183989

1 reference

15 January 2018